Regeneron Pharmaceuticals ((REGN)), Sanofi SA ((SNY)), Sanofi ((SNYNF)), Sanofi ((DE:SNW)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent clinical study update from Regeneron Pharmaceuticals and Sanofi focuses on the investigation of Itepekimab, an anti-IL-33 monoclonal antibody, to understand its effects on airway inflammation in patients with Chronic Obstructive Pulmonary Disease (COPD). Officially titled ‘A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD)’, the study aims to explore the drug’s mechanism in former and current smokers with COPD, highlighting its significance in potentially advancing COPD treatment options.
The intervention being tested is Itepekimab, administered subcutaneously every two weeks over a 12-week period. This drug is intended to reduce airway inflammation in COPD patients, potentially offering a new treatment avenue for this chronic condition.
The study design is interventional with a single-group model, focusing on treatment as the primary purpose. It is an open-label study, meaning no masking is involved, allowing all participants and researchers to know the treatment being administered.
The study commenced on May 19, 2022, with a primary completion date that aligns with the 12-week treatment period followed by a 20-week follow-up. The last update was submitted on August 20, 2025, indicating ongoing data analysis and updates.
This study’s outcomes could significantly impact Regeneron and Sanofi’s stock performance, as positive results may enhance investor confidence and market position in the COPD treatment landscape. The study’s focus on a novel treatment mechanism could also influence industry competitors to explore similar avenues.
The study is currently completed, with further details available on the ClinicalTrials portal.